This site has been permanently archived. This is a static copy provided by the University of Southampton.
<> "The repository administrator has not yet configured an RDF license."^^ .
<> .
.
"Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats"^^ .
"Several studies suggest that cyclooxygenase (COX)-2 plays a pivotal role in the progression of ischemic brain damage. In the present study, we investigated the effects of selective inhibition of COX-2 with nimesulide (12 mg/kg) and selective inhibition of COX-1 with valeryl salicylate (VAS, 12-120 mg/kg) on prostaglandin E2 (PGE2) levels, myeloperoxidase (MPO) activity, Evans Blue (EB) extravasation and infarct volume in a standardized model of transient focal cerebral ischemia in the rat. Postischemic treatment with nimesulide markedly reduced the increase in PGE2 levels in the ischemic cerebral cortex 24 h after stroke and diminished infarct size by 48 % with respect to vehicle-treated animals after 3 days of reperfusion. Furthermore, nimesulide significantly attenuated the blood-brain barrier (BBB) damage and leukocyte infiltration (as measured by EB leakage and MPO activity, respectively) seen at 48 h after the initial ischemic episode. These studies provide the first experimental evidence that COX-2 inhibition with nimesulide is able to limit BBB disruption and leukocyte infiltration following transient focal cerebral ischemia. Neuroprotection afforded by nimesulide is observed even when the treatment is delayed until 6 h after the onset of ischemia, confirming a wide therapeutic window of COX-2 inhibitors in experimental stroke. On the other hand, selective inhibition of COX-1 with VAS had no significant effect on the evaluated parameters. These data suggest that COX-2 activity, but not COX-1 activity, contributes to the progression of focal ischemic brain injury, and that the beneficial effects observed with non-selective COX inhibitors are probably associated to COX-2 rather than to COX-1 inhibition. "^^ .
"2007-02" .
.
"100" .
"4" .
.
"Blackwell Publishing"^^ .
.
.
"Journal of Neurochemistry"^^ .
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
"Sean"^^ .
"Murphy"^^ .
"Sean Murphy"^^ .
.
"Olga Sonia"^^ .
"Leon"^^ .
"Olga Sonia Leon"^^ .
.
"Eduardo"^^ .
"Candelario-Jalil"^^ .
"Eduardo Candelario-Jalil"^^ .
.
"Bernd"^^ .
"Fiebich"^^ .
"Bernd Fiebich"^^ .
.
"Anthony"^^ .
"Turner"^^ .
"Anthony Turner"^^ .
.
"Michel"^^ .
"Garcia-Cabrera"^^ .
"Michel Garcia-Cabrera"^^ .
.
"Armando"^^ .
"Gonzalez-Falcon"^^ .
"Armando Gonzalez-Falcon"^^ .
.
.
.
.
.
"Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats (PDF)"^^ .
.
.
.
.
.
.
.
.
"J_Neurochem_2007_Candelario-Jalil_et_al.pdf"^^ .
.
.
"Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats (Image (PNG))"^^ .
.
.